Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review

Table 2

Quantitative data for trial outcomes (dichotomous).

DRV/r versus LPV/r (ARTEMIS)	Events, DRV/r	Total, DRV/r	Events, LPV/r	Total, LPV/r	RR (95% CI)
Mortality (192 weeks)	4	343	7	346	0.58 (0.17–1.95)
Mortality (96 weeks)	1	343	3	346	0.34 (0.04–3.22)
Mortality (48 weeks)	1	343	3	346	0.34 (0.04–3.22)
≥1 SAE (192 weeks)	55	343	72	346	0.77 (0.56–1.06)
≥1 SAE (96 weeks)	34	343	55	346	0.62 (0.42–0.93)
≥1 SAE (48 weeks)	25	343	41	346	0.62 (0.38–0.99)
PVL < 50 copies/mL (192 weeks)	236	343	198	346	1.20 (1.07–1.35)
PVL < 50 copies/mL (96 weeks)	271	343	246	346	1.11 (1.02–1.21)
PVL < 50 copies/mL (48 weeks)	254	343	226	346	1.13 (1.03–1.25)
DRV/r versus DTG (FLAMINGO)	Events, DRV/r	Total, DRV/r	Events, DTG	Total, DTG	RR (95% CI)
≥1 SAE (96 weeks)	36	245	21	243	1.70 (1.02–2.83)
≥1 SAE (48 weeks)	13	245	26	243	0.50 (0.26–0.94)
PVL < 50 copies/mL (96 weeks)	164	245	194	243	0.84 (0.75–0.93)
PVL < 50 copies/mL (48 weeks)	186	245	192	243	0.96 (0.87–1.06)
DRV/r versus RAL (ACTG 5257)	Events, DRV/r	Total, DRV/r	Events, RAL	Total, RAL	RR (95% CI)
Mortality (96 weeks)	13	601	6	603	2.17 (0.83–5.68)
Elevated blood bilirubin (96 weeks)	466	601	444	603	1.05 (0.99–1.12)
PVL < 50 copies/mL (96 weeks)	461	601	494	603	0.94 (0.88–0.99)
DRV/r versus ATV/r (ACTG 5257)	Events, DRV/r	Total, DRV/r	Events, ATV/r	Total, ATV/r	RR (95% CI)
Mortality (96 weeks)	13	601	10	605	1.31 (0.58–2.96)
Elevated blood bilirubin (96 weeks)	466	601	286	605	1.64 (1.49–1.80)
PVL < 50 copies/mL (96 weeks)	461	601	455	605	1.02 (0.96–1.09)

RR, risk ratio; PVL, plasma viral load; SAE, severe adverse event; CI, confidence interval; DRV/r, ritonavir boosted darunavir-based regimen; DTG, dolutegravir-based regimen; LPV/r, ritonavir boosted lopinavir-based regimen; ATV/r, ritonavir boosted atazanavir-based regimen; RAL, raltegravir-based regimen.